Krajina: Spojené štáty
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
GEMTUZUMAB OZOGAMICIN (UNII: 8GZG754X6M) (GEMTUZUMAB OZOGAMICIN - UNII:8GZG754X6M)
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
GEMTUZUMAB OZOGAMICIN
GEMTUZUMAB OZOGAMICIN 5 mg in 5 mL
INTRAVENOUS
PRESCRIPTION DRUG
MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older. MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older. MYLOTARG is contraindicated in patients with a history of hypersensitivity to the active substance in MYLOTARG or any of its components or to any of the excipients. Reactions have included anaphylaxis [see Warnings and Precautions (5.2), Adverse Reactions (6)] . Risk Summary Based on its mechanism of action and findings from animal studies [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)] , MYLOTARG can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on MYLOTARG use in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, gemtuzumab ozogamicin caused embryo-fetal toxicity, including structural abnormalities and alteration
MYLOTARG (gemtuzumab ozogamicin) for injection is a white to off-white lyophilized cake or powder supplied in a carton (NDC 0008-4510-01) containing one 4.5 mg single-dose vial [see Dosage and Administration (2)] . Refrigerate (2°C to 8°C; 36°F to 46°F) MYLOTARG vials and store in the original carton to protect from light. DO NOT FREEZE. MYLOTARG is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
Biologic Licensing Application
MYLOTARG- GEMTUZUMAB OZOGAMICIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MYLOTARG SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MYLOTARG. MYLOTARG™ (GEMTUZUMAB OZOGAMICIN) FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2000 WARNING: HEPATOTOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ HEPATOTOXICITY, INCLUDING SEVERE OR FATAL HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), HAS BEEN REPORTED IN ASSOCIATION WITH THE USE OF MYLOTARG. (5.1, 6.1) RECENT MAJOR CHANGES Dosage and Adminstration, Instructions for Reconstitution, Dilution, and Administration (2.4) 08/2021 INDICATIONS AND USAGE MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older (1.1). treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older (1.2). DOSAGE AND ADMINISTRATION Newly-diagnosed, de novo AML (combination regimen) Adults: – – Pediatric patients 1 month and older: – – – Newly-diagnosed AML (single-agent regimen): Adults: – – Relapsed or refractory AML (single-agent regimen): – _Induction:_ 3 mg/m (up to one 4.5 mg vial) on Days 1, 4, and 7 in combination with daunorubicin and cytarabine (2.2). 2 _Consolidation:_ 3 mg/m on Day 1 (up to one 4.5 mg vial) in combination with daunorubicin and cytarabine (2.2). 2 3 mg/m for patients with body surface area (BSA) 0.6 m or greater (2.2). 2 2 0.1 mg/kg for patients with BSA less than 0.6 m (2.2). 2 See Full Prescribing Information for complete dosing information (2.2). _Induction:_ 6 mg/m (not limited to one 4.5 mg vial) on Day 1 and 3 mg/m (not limited to one 4.5 mg vial) on Day 8 (2.2). 2 2 _Continuation:_ For patients without ev Prečítajte si celý dokument